Fig. 1: A genome-wide CRISPR activation screen identifies restriction factors for influenza B virus.
From: Cellular glycan modification by B3GAT1 broadly restricts influenza virus infection
a Schematic of the CRISPR activation screening approach used. sgRNA = single guide RNA. b sgRNA read counts detected for each round of infection by B/Yamagata/16/1988 (Yam/88) during the screen. Each point represents a unique sgRNA for each independent screen replicate and sgRNAs not detected are omitted from the graph. c Ranked scores for upregulated genes after three rounds of Yam/88 infection. The top six ranked genes are labeled. d Expression of the indicated genes in A549 dCas9-VP64 cells after activation with the most enriched sgRNAs from the screen or a non-targeting control sgRNA, measured using qRT-PCR (mean with SEM, N = 4 experiments, B4GALNT2 *p = 0.0286, B3GAT1 *p = 0.0286, TGM2 *p = 0.0286, ANXA11 p = 0.8857). ND = not detected. e Percent of cells infected with Yam/88 PB1-mNeon (MOI = 0.6, 24 HPI, single cycle) in the indicated sgRNA-activated cell lines, measured using flow cytometry (mean with SEM, N = 4 experiments, B4GALNT2 *p = 0.0286, B3GAT1 *p = 0.0286, NXPE4 *p = 0.0286, TGM2 p = 0.6857, ANXA11 p = 0.8857, GPHA2 p = 0.6857). Statistical comparisons were all calculated with respect to the non-targeting control. All statistical analyses were performed using a two-tailed Mann-Whitney U test. * indicates p < 0.05, ns = not significant, nt = not tested. Source data are provided as a Source Data file.
